Monday, February 07, 2011 4:52:47 PM
As filed with the Securities and Exchange Commission on February 4, 2011
Registration No. 333-161922
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
Post-Effective Amendment No. 2 to
FORM S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
______________
NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation or organization) 2834
(Primary Standard Industrial
Classification Code Number) 04-3321804
(I.R.S. employer
identification number)
One Gateway Center
Suite 504
Newton, Massachusetts 02458
(617) 244-1616
(Address and telephone number of principal executive offices)
Harry S. Palmin
President and Chief Executive Officer
Novelos Therapeutics, Inc.
One Gateway Center, Suite 504
Newton, Massachusetts 02458
(617) 244-1616
(Name, address and telephone number of agent for service)
Copy to:
Paul Bork, Esq.
Foley Hoag LLP
155 Seaport Boulevard
Boston, Massachusetts 02110
(617) 832-1000
________________
Approximate date of commencement of proposed sale to the public: Not applicable.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 (“Securities Act”), check the following box. ¨
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company x
(Do not check if a smaller reporting company)
--------------------------------------------------------------------------------
DEREGISTRATION OF UNSOLD SECURITIES
--------------------------------------------------------------------------------
On September 15, 2009, Novelos Therapeutics, Inc. (the "Company") filed a Registration Statement on Form S-1 (File No. 333-161922) with the Securities and Exchange Commission (the "Commission"), which was declared effective on February 12, 2010 and subsequently amended by Post-Effective Amendment No. 1 filed on April 14, 2010 (the "Registration Statement"). The Registration Statement initially registered the resale, from time to time, of 19,000,000 shares (the "Shares") of the Company's common stock, par value $0.00001 per share. The Shares were registered to permit resales of such Shares by the selling stockholders, as named in the Registration Statement, who acquired preferred stock convertible into Shares in connection with the Company's private placements of the Company’s Series E preferred stock in 2009.
In accordance with the undertaking of the Company contained in the Registration Statement pursuant to Item 512 of Regulation S-K, the Company is filing this Post-Effective Amendment No. 2 to the Registration Statement to deregister the Shares that were previously registered under the Registration Statement, 15,601,703 of which remain, to the best of the Registrant’s knowledge based on the information available to it, unsold as of the date hereof. The Company is seeking to deregister these Shares because its obligations to keep the Registration Statement effective pursuant to the terms of its registration rights agreements with the selling stockholders have terminated with respect to all the Shares. The Registration Statement is hereby amended to effect the deregistration of these 15,601,703 Shares.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this post-effective amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Newton, Commonwealth of Massachusetts, on February 4, 2011.
NOVELOS THERAPEUTICS, INC.
By: /s/ Harry S. Palmin
February 4, 2011 Harry S. Palmin
President and Chief Executive Officer
In accordance with the requirements of the Securities Act of 1933, this post-effective amendment to the registration statement was signed by the following persons in the capacities and on the dates stated:
Signature Title Date
/s/ Harry S. Palmin Chief Executive Officer and Director February 4, 2011
Harry S. Palmin ( principal executive officer )
/s/ Joanne M. Protano Chief Financial Officer February 4, 2011
Joanne M. Protano ( principal financial officer and principal accounting officer)
/s/ * Chairman of the Board of Directors February 4, 2011
Stephen A. Hill
/s/ * Director February 4, 2011
Michael J. Doyle
/s/ * Director February 4, 2011
Sim Fass
/s/ * Director February 4, 2011
James S. Manuso
/s/ * Director February 4, 2011
David B. McWilliams
/s/ * Director February 4, 2011
Howard M. Schneider
* /s/ Harry S. Palmin as attorney-in-fact.
Recent CLRB News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:04:30 PM
- Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides • GlobeNewswire Inc. • 05/29/2024 10:40:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/24/2024 08:46:56 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/16/2024 10:05:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 10:45:17 AM
- Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 05/14/2024 10:40:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:20 AM
- Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day • GlobeNewswire Inc. • 05/08/2024 10:40:23 AM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:40:00 AM
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2024 10:40:00 AM
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 10:40:00 AM
- Cellectar Biosciences to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/14/2024 12:52:48 PM
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer • GlobeNewswire Inc. • 03/04/2024 11:40:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:31:57 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:29:43 PM
- Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:03:04 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 01:00:28 PM
- Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study • GlobeNewswire Inc. • 01/30/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:30:40 PM
- Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million • GlobeNewswire Inc. • 01/25/2024 11:40:00 AM
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient • GlobeNewswire Inc. • 01/22/2024 11:40:00 AM
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data • GlobeNewswire Inc. • 01/16/2024 11:40:00 AM
- Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results • GlobeNewswire Inc. • 01/12/2024 11:44:16 AM
- Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting • GlobeNewswire Inc. • 01/11/2024 11:40:00 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM